New drug GSK4532990 shows promise in early NASH trial
NCT ID NCT06104319
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested a single dose of an experimental drug called GSK4532990 in 61 adults with non-alcoholic fatty liver disease (NASH). The goal was to see how the drug moves through the body, how it affects the liver, and whether it is safe. Participants were followed for about 24 to 36 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Chula Vista, California, 91911, United States
-
GSK Investigational Site
Montclair, California, 91763, United States
-
GSK Investigational Site
San Diego, California, 91911, United States
-
GSK Investigational Site
San Diego, California, 91942, United States
-
GSK Investigational Site
Brandon, Florida, 33511, United States
-
GSK Investigational Site
Miami, Florida, 33155, United States
-
GSK Investigational Site
Miami, Florida, 33173, United States
-
GSK Investigational Site
Miami Lakes, Florida, 33014, United States
-
GSK Investigational Site
Indianapolis, Indiana, 46202, United States
-
GSK Investigational Site
El Dorado, Kansas, 67042, United States
-
GSK Investigational Site
Marrero, Louisiana, 70072, United States
-
GSK Investigational Site
Austin, Texas, 78745, United States
-
GSK Investigational Site
San Antonio, Texas, 78215, United States
-
GSK Investigational Site
San Antonio, Texas, 78240, United States
Conditions
Explore the condition pages connected to this study.